Dyspepsia Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug-Induced Dyspepsia, and Others), By Drug Type (Branded and Generic), By Prescription (Without Prescription Drugs and Prescription Drugs), By Route of Administration (Oral and Injectable), By Distribution Channel (Direct Tender and Retail Sales) and Region

Dyspepsia Market size was valued at US$ 9,326.8 million in 2023 and is poised to grow at 4.5% CAGR from 2024–2030. Dyspepsia, also known as indigestion, encompasses a range of upper abdominal discomfort or pain, often accompanied by bloating, belching, and nausea. It is a common gastrointestinal disorder that can significantly impact individuals quality of life. According to the World Health Organization (WHO) and the National Institutes of Health (NIH), dyspepsia affects a substantial portion of the global population and it was estimated that around 25-40% of adults experienced dyspeptic symptoms at least occasionally. These symptoms may result from various underlying causes, including gastroesophageal reflux disease (GERD), peptic ulcers, gastritis, and functional dyspepsia.

Functional dyspepsia, a subtype of dyspepsia with no identifiable structural or biochemical abnormalities, has been a subject of particular interest. Studies suggest that it affects approximately 10-20% of the population in Western countries. The burden of dyspepsia is not limited to its prevalence alone it also contributes to a substantial economic impact due to healthcare utilization, including doctor visits, diagnostic tests, and treatments. In the United States, for instance, direct and indirect costs associated with functional dyspepsia have been estimated to be in the billions of dollars annually. Furthermore, dyspepsia is often linked to lifestyle factors such as diet, stress, and smoking. Obesity, too, is a contributing factor, as it can exacerbate symptoms and increase the risk of GERD. While lifestyle modifications and dietary changes are recommended as initial management strategies, pharmacological interventions may also be necessary for some individuals.  

Dyspepsia Market Key Developments

• In April 2023, Sanofi announced that it had completed the acquisition of Provention Bio, Inc. This acquisition has helped the company in the expansion of its business in general medicine.
• In July 2022, ANI Pharmaceuticals, Inc. announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company.